[A21-08] Carfilzomib (multiple myeloma) - Benefit assessment according to §35a Social Code Book V
Last updated 15.07.2021
Project no.:
A21-08
Commission:
Commission awarded on 15.01.2021 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Cancer
Adult patients with multiple myeloma who have received at least one prior therapy
Added benefit not proven.
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A17-38 | Carfilzomib (multiple myeloma) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| G16-11 | Carfilzomib (multiple myeloma; combination with dexamethasone alone) – Assessment according to § 35a (para. 1, sentence 10) Social Code Book V | Commission completed |
| G15-16 | Carfilzomib - Assessment according to §35a (para. 1., sentence 10) Social Code Book V | Commission completed |
| A21-70 | Carfilzomib (multiple myeloma) - Addendum to Commission A21-08 | Commission completed |
Federal Joint Committee (G-BA)
2021.07.15 A G-BA decision was published.